Compare Cassava Sciences Inc (FLNA) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs D Wave Quantum Inc — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while D Wave Quantum Inc trades at $17.45 (market cap $6.77B). The key difference: D Wave Quantum Inc is far larger — about 127.4× Cassava Sciences Inc's market cap, and D Wave Quantum Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | QBTS | |
|---|---|---|
Market Cap | $53.14M | $6.77B |
Sector | Health | Technology |
52-Week High | $4.64 | $44.78 |
52-Week Low | $1.09 | $12.98 |
Enterprise Value | -$33.43M | $6.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
D-Wave Quantum (QBTS) trades at $17.67, down 6.75% on the day, amid bearish technical signals despite unanimous analyst buy ratings with a $39.86 consensus target. The quantum computing firm shows severe fundamental challenges with a -$355M net loss in 2025, negative profit margins exceeding -1400%, and a sky-high P/S ratio of 501, though it maintains a strong gross margin of 66%. Recent news highlights its Nasdaq listing transfer and IDC MarketScape leadership recognition while sector-wide volatility pressures speculative quantum stocks.
The outlook presents a stark dichotomy between Wall Street's bullish price targets and the company's deep losses and cash burn. Investment opportunity hinges on speculative growth in commercial quantum adoption, but significant risks include unsustainable valuation, prolonged path to profitability, heavy reliance on financing activities for cash flow, and intense competition in a pre-commercialization sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
